Current options for the treatment of Paget’s disease of the bone

Review

(3003) Views  (1169) Full article downloads

Authors: Daniela Merlotti, Luigi Gennari, Giuseppe Martini, et al

Published Date July 2009 Volume 2009:1 Pages 107 - 120

DOI: http://dx.doi.org/10.2147/OARRR.S4504

Daniela Merlotti, Luigi Gennari, Giuseppe Martini, Ranuccio Nuti

Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Siena, Italy

Abstract: Paget’s disease of bone (PDB) is a chronic bone remodeling disorder characterized by increased osteoclast-mediated bone resorption, with subsequent compensatory increases in new bone formation, resulting in a disorganized mosaic of woven and lamellar bone at affected skeletal sites. This disease is most often asymptomatic but can be associated with bone pain or deformity, fractures, secondary arthritis, neurological complications, deafness, contributing to substantial morbidity and reduced quality of life. Neoplastic degeneration of pagetic bone is a relatively rare event, occurring with an incidence of less than 1%, but has a grave prognosis. Specific therapy for PDB is aimed at decreasing the abnormal bone turnover and bisphosphonates are currently considered the treatment of choice. These treatments are associated with a reduction in plasma alkaline phosphatase (ALP) activity and an improvement in radiological and scintigraphic appearance and with a reduction in bone pain and bone deformity, Recently, the availability of newer, more potent nitrogen-containing bisphosphonates has improved treatment outcomes, allowing a more effective and convenient management of this debilitating disorder.

Keywords: Paget’s disease of bone, bisphosphonates, aminobisphosphonates, bone remodeling